Practo has evolved from a simple doctor discovery platform into India’s most comprehensive digital healthcare ecosystem. By integrating B2B practice management (Practo Ray) with a massive B2C patient gateway, the company structurally orchestrates over ₹3,500 Cr in GMV annually, connecting 50M+ patients with 500k+ verified doctors.
Investors should note the structural inflexion point: after years of heavy cash burn, Practo secured its first full year of profitability in FY25, generating ₹15 Cr in operating EBITDA. With robust unit economics established, an expanding footprint in the UAE, and revived IPO aspirations, Practo represents a highly de-risked asset poised to capitalize on the digitization of emerging market healthcare.
Practo operates as a dual-sided marketplace and SaaS provider, fundamentally digitizing the opaque and fragmented Indian healthcare sector. On the B2B side, it equips doctors and clinics with Practo Ray and Insta (Hospital Management Systems), embedding itself deeply into the daily operational workflows of healthcare providers.
The consumer (B2C) application aggregates this digitized supply, allowing patients to seamlessly search for specialists, book appointments, consult via telemedicine, order medicines, and manage electronic health records (EHR). This closed-loop ecosystem creates immense data liquidity, capturing over 4 Crore structured clinical data points annually.
Strategically, Practo has successfully transitioned from an aggressive growth-at-all-costs mindset to a sustainable, unit-economic-positive engine. By shedding non-core peripheral bets and enforcing a sharp focus on its Care Navigation business, Practo turned a -₹162 Cr EBITDA loss in FY22 into a resilient, cash-generating business by FY25.
Shashank ND struggles to share his father's medical reports with an American doctor pre-surgery, exposing the lack of digitized health records.
Realizing doctors lacked internet, Shashank & Abhinav Lal launch Practo Ray software, using a difficult "feet-on-street" sales model.
With doctors digitized, Practo.com launches, instantly bridging the gap for patients seeking verified doctors. Sequoia (Peak XV) invests.
Founders steer the company through massive restructuring to achieve 6 consecutive quarters of EBITDA profitability.
The genesis of Practo is rooted in genuine consumer frustration. In 2008, a young NIT Surathkal graduate, Shashank ND, was faced with a daunting task: sending physical copies of his father's complex medical records to a physician in the US for a second opinion regarding knee surgery. The friction of the analog process illuminated a massive gap in the Indian healthcare landscape.
Partnering with his classmate and technical whiz, Abhinav Lal, the duo skipped campus placements to build a solution. They rapidly learned that building a consumer search engine was impossible if doctors didn't have digital schedules. This forced a gritty, unglamorous phase of selling SaaS (Practo Ray) door-to-door to clinics—a notoriously difficult feat in 2009 India.
This foundational struggle is why Practo succeeded where others failed. By enduring the "startup graveyard" of selling B2B software to resistant doctors, Shashank and Abhinav built the definitive, supply-side moat that later enabled their consumer marketplace to explode. Their resilience reflects a rare breed of founders capable of managing extreme hyper-growth and, more recently, orchestrating a disciplined pivot to profitability.
Patients relied entirely on word-of-mouth to find specialists. There was zero transparency regarding a doctor's credentials, real patient reviews, or actual appointment availability, leading to immense friction for sick patients.
Doctors managed appointments in physical diaries and stored patient histories in paper files. This lack of digitization caused severe operational bottlenecks, lost records, and prevented any form of data-driven care.
A patient's journey—consultation, diagnostics, and pharmacy—was entirely siloed. Patients had to carry physical files between multiple disconnected nodes, resulting in high out-of-pocket costs and poor clinical outcomes.
Structurally, this inefficiency cost the Indian economy billions in wasted healthcare resources and delayed diagnoses. By operating in silos, the ecosystem prevented the compounding benefits of data continuity. Practo recognized that without a unified digital infrastructure, scaling quality healthcare delivery to a billion people would be fundamentally impossible.
Practo solved the fragmentation by building a vertically integrated healthcare operating system. Instead of just creating a directory, they first built the infrastructure (SaaS) that clinics use to run their daily business. Once the supply side was digitized, they layered on a massive consumer-facing discovery and booking engine.
The key innovation was the seamless synchronization between the doctor's calendar (Practo Ray) and the patient's app. When a patient books an appointment, it instantly reflects in the clinic's software. Post-consultation, the digital prescription flows back to the patient's app, allowing them to instantly order medicines or book lab tests.
Consumers adopted it because it eliminated waiting room anxiety and provided transparent "Clinic Excellence Scores." Doctors adopted it because the SaaS tool reduced administrative overhead while the marketplace drove high-intent, new patient acquisition, fundamentally increasing their practice revenue.
Enterprise-grade practice and hospital management software handling billing, EHR, and scheduling.
B2C platform for searching 500k+ verified doctors based on proximity, specialty, and user reviews.
Instant 24/7 video and chat consultations, capturing critical early-stage patient triage data.
Integrated fulfillment of e-pharmacy orders and at-home diagnostic testing to complete the loop.
Practo utilizes a highly diversified monetization engine, insulating it from single-market shocks. The foundation is a predictable B2B SaaS subscription model where clinics and hospitals pay recurring fees (monthly/annually) to utilize Practo Ray and Insta. This ensures high-margin, sticky revenue.
On top of this, the company extracts value via a transactional marketplace model. Practo charges a take-rate (commission) on successful online consultations and physical appointment bookings facilitated through its platform.
The unit economics are highly compelling. By leveraging the initial doctor discovery as a low-CAC (Customer Acquisition Cost) entry point, Practo cross-sells higher-margin ancillary services like medicine delivery and diagnostic testing. This flywheel drove contribution margins from -1% in FY22 to a robust 46% in FY25.
Lead: Peak XV Partners.
Impact: Initial scale and tech infrastructure build.
Lead: Tencent.
Impact: Massive user acquisition and geographic expansion.
Lead: Tencent.
Impact: Market penetration and product diversification.
Lead: AIA Group.
Impact: Navigating Covid-19 telehealth surge.
$249M
Key Backers: Peak XV Partners (Sequoia India), Tencent, CapitalG, Matrix Partners (Z47), AIA Group, RTP Global.
Practo’s capitalization table features a mix of aggressive growth VCs (Peak XV) and strategic corporate investors (Tencent, AIA Group). The heavy funding rounds between 2015-2017 were utilized for rapid land-grab, acquiring smaller startups (FitHo, Qikwell, InstaHealth), and establishing a dominant brand. The shift toward debt financing and smaller, targeted equity rounds post-2020 reflects a deliberate transition from cash-burning user acquisition to establishing sustainable, profitable unit economics.
Revenue stabilized in FY25 at ₹234 Cr as the company strategically exited low-margin businesses, resulting in an immense bottom-line improvement from -₹99 Cr EBITDA (FY23) to +₹15 Cr EBITDA (FY25).
This 109% turnaround from severe losses to profitability signals that Practo's core "Care Navigation" business is highly scalable with expanding contribution margins (reaching 46% in FY25).
Practo is heavily investing in AI tools for clinical decision-making, symptom triage, and smart search. This positions them to reduce misdiagnoses and increase platform lock-in for doctors relying on their advanced analytics.
Leveraging strong B2B roots (Insta HMS has 15% market share in UAE), Practo launched B2C operations in Dubai and Abu Dhabi in FY25, achieving a ₹100 Cr GMV run-rate within weeks of launch.
Deploying "Clinic Excellence Scores" and publishing Patient-Reported Outcome Metrics (PROMs). They are the first Indian digital health firm to do so, driving a massive brand trust advantage.
Practo did something incredibly difficult: they shrank to grow profitably. Instead of pursuing vanity metrics across every possible healthcare vertical, they doubled down on their core strength—the Care Navigation business. By focusing intensely on high-LTV patients and improving doctor retention (98% for their Insta HMS software), they stabilized revenue while drastically cutting cash burn.
The scaling flywheel is now highly efficient. As they expand into Tier 2/3 Indian cities (which grew 50% YoY recently) and high-ARPU international markets like the UAE, their underlying SaaS infrastructure acts as a zero-CAC Trojan horse. Once a hospital uses Practo Ray, lighting up the B2C consumer marketplace for that region requires minimal marginal marketing spend.
| Company | Core Strength | B2B SaaS Integration | Profitability Status | Market Position |
|---|---|---|---|---|
| Practo | Full-stack ecosystem (B2B + B2C) | High (Practo Ray / Insta) | Profitable (FY25) | Market Leader |
| Apollo 24/7 | Physical hospital network | Internal only | Loss Making | Strong Challenger |
| Tata 1mg | E-Pharmacy & Diagnostics | Low | Loss Making | Category Leader (Rx) |
| MediBuddy | Corporate Health / Telemedicine | Medium | Loss Making | B2B2C Leader |
| Lybrate | Online Q&A / Consultations | Low | Nearing Breakeven | Niche Player |
Hospitals using Practo's Insta HMS or clinics on Practo Ray have their entire historical EHR and billing tied to the platform. Migration is painful, leading to a reported 98% B2B retention rate.
Every new doctor added makes the B2C app more valuable to patients. Every new patient booked makes the SaaS product indispensable to doctors. This limits the threat of single-sided upstarts.
As one of the only Indian healthtechs with ISO 27001 certification and QAI accreditation for medical quality, Practo owns the "trust" vector in an industry plagued by quackery and fraud.
Practo attempted to expand into fitness, gym subscriptions, and hardware too rapidly, bleeding capital and losing focus on core clinical outcomes.
Response: Divested non-core assets, deeply cut burn rate, and pivoted entirely back to the high-margin "Care Navigation" software and marketplace.
Heavy discounting wars initiated by well-funded rivals (Tata 1mg, PharmEasy) severely squeezed margins in the medicine delivery segment.
Response: Refused to play the deep discounting game. Practo positioned its pharmacy as a convenience add-on post-consultation rather than a standalone loss-leader.
Initial assumptions that doctors would adopt SaaS organically failed miserably due to low digital literacy and resistance to transparent tax/billing.
Response: Built a massive, expensive "feet-on-street" sales force. While costly, it built the insurmountable supply-side moat they rely on today.
Telemedicine operations faced significant legal ambiguity in India prior to 2020, risking sudden operational shutdowns.
Response: Worked closely with government bodies to help frame the official Telemedicine Practice Guidelines issued in 2020, securing their legal operating foundation.
Indian Healthcare Market (2026)
Digital Health & Telemedicine
Practo Near-Term Revenue Potential
| Key Financial Metric | FY23 | FY24 | FY25 | Investor Signal |
|---|---|---|---|---|
| GMV | N/A | ₹3,500 Cr | ₹3,500 Cr+ | Scale Validated |
| Revenue | ₹196 Cr | ₹240 Cr | ₹234 Cr | Growth Stabilizing |
| Contribution Margin | ~10% | 40% | 46% | Excellent Economics |
| Operating EBITDA | -₹99 Cr | -₹17 Cr | +₹15 Cr | Cash Flow Positive |
From an investor lens, Practo has completed the "Valley of Death" transition. The slight revenue contraction between FY24 (₹240 Cr) and FY25 (₹234 Cr) is a positive signal—it reflects the deliberate shedding of low-quality, subsidized GMV in favor of highly profitable core transactions.
With contribution margins hitting 46%, the unit economics are now fully self-sustaining. The structural implication is that Practo no longer requires external VC capital to survive; any future capital raised (or an IPO) will be purely for geographic expansion (e.g., doubling down on their explosive UAE growth) or strategic AI acquisitions.
"We've demonstrated that digital healthcare can scale with both impact and financial discipline... We are now building an institution that lasts."
— Shashank ND, CEO (FY25 Annual Letter)
The Indian healthcare sector is undergoing a massive structural re-rating. Driven by rising domestic incomes, rapid smartphone penetration, and a post-pandemic shift in consumer behavior, digital health adoption is accelerating faster in India than in Western markets.
Crucially, the Indian government is acting as an accelerator. The rollout of the Ayushman Bharat Digital Mission (ABDM) and the creation of unified Health IDs (ABHA) is standardizing digital health infrastructure at a national level. Practo, with its massive existing repository of digitized clinic data, is perfectly positioned to serve as the private-sector interface for this public grid.
Global private equity is taking notice. Capital is rotating away from pure hospital real estate toward asset-light, highly scalable tech models. Practo’s ability to generate ₹3,500 Cr in GMV without owning a single hospital bed epitomizes the capital efficiency investors are currently rewarding.
Increased Out-Patient Department (OPD) insurance coverage is driving patients to organized, verifiable networks like Practo over cash-based local clinics.
Government pushes for digitized health records legitimize Practo's core SaaS offering, forcing hold-out doctors to adopt digital systems.
Practo's expansion into the UAE and broader MENA region captures the highly lucrative inbound medical tourism pipeline into premier Indian hospitals.
Conglomerate-backed rivals (Tata 1mg, Reliance Netmeds) possess deeper pockets for discounting. Impact: Could cap Practo's revenue ceiling in the lucrative pharmacy delivery segment if price wars resume.
Handling 50M+ patient records exposes Practo to severe regulatory scrutiny under India's new Digital Personal Data Protection (DPDP) Act. Impact: A single data breach could destroy brand trust and invite massive fines.
As Apollo and Fortis build out their own digital ecosystems (e.g., Apollo 24/7), they may restrict Practo's access to their premier doctors. Impact: Loss of high-end supply, forcing reliance on independent clinics.
Scaling B2C operations in the UAE requires localized GTM strategies and navigating complex Middle Eastern healthcare regulations. Impact: Potential capital sink if unit economics fail to replicate outside India.
With consecutive profitable quarters achieved in FY24/FY25, the company has officially revived IPO plans (12-18 month timeline). Indian public markets are currently highly receptive to profitable tech startups.
A buyout by a global player (e.g., Amazon Health) or an Indian conglomerate. Less likely now as Practo's valuation and independence have calcified through profitability.
Practo uses its profitable cash flow to acquire smaller, distressed healthtech players, acting as an aggregator before an eventual mega-IPO.
Practo didn't launch a consumer app on day one. They spent years grinding out B2B SaaS sales to digitize doctors' calendars. By the time they launched the B2C marketplace, they already had a proprietary, locked-in supply network that competitors couldn't scrape or replicate.
When capital dried up, Practo aggressively pruned non-core vanity projects (like fitness tracking). By focusing strictly on the high-margin "Care Navigation" flywheel, they executed a textbook turnaround, proving that hyper-growth discipline pays off.
Using a SaaS product (Practo Ray) as a trojan horse into clinics creates a natural, low-cost funnel for the consumer marketplace. Patients inherently trust the platform their doctor uses, drastically lowering consumer CAC compared to pure-play D2C health brands.
In healthcare, trust eclipses UI/UX. By enforcing strict doctor verification, obtaining ISO 27001 security certifications, and publishing clinical outcome data, Practo institutionalized trust, turning it into a tangible competitive moat against low-quality upstarts.
With the achievement of FY25 profitability, the narrative surrounding Practo has fundamentally shifted. The company is no longer reliant on venture life-support. This financial autonomy grants the board significant leverage in determining the optimal exit vehicle, favoring a public market debut.
The Catalyst: Indian public markets (BSE/NSE) are awarding premium multiples to profitable tech platforms (e.g., Zomato, PolicyBazaar). Practo’s 109% EBITDA turnaround makes for a pristine IPO prospectus.
The Hurdle: Demonstrating sustained double-digit topline growth alongside profitability to justify a rich SaaS-like multiple.
The Catalyst: A global tech giant (Amazon, Google Health) or an aggressive Indian conglomerate (Reliance) seeking an instant, dominant footprint in India’s healthcare OS.
The Hurdle: Practo’s late-stage valuation expectations and current profitable independence make an outright acquisition financially prohibitive for most domestic buyers.
The Catalyst: A massive Private Equity player buys out early VCs (Peak XV, Tencent) to restructure the company, strip out any remaining inefficiencies, and scale the highly profitable SaaS arm globally before going public.
The Hurdle: Requires massive capital deployment in an emerging market, though the UAE expansion proves cross-border viability.
Moving beyond scheduling to actual clinical assistance. By deploying LLMs for symptom triage and diagnostic support, Practo can embed itself into the clinical outcome, not just the administrative workflow.
With a stated goal to reach 10% user penetration in Dubai and double international revenue in FY26, the Middle East offers a high-ARPU proving ground for Practo's technology export strategy.
Expanding B2B2C offerings directly to employers (insurance partnerships, employee wellness plans) to secure recurring, high-volume patient pipelines bypassing direct consumer marketing.
Practo has executed one of the most difficult maneuvers in the venture playbook: pivoting from a cash-burning growth narrative to a self-sustaining, profitable institution. By enforcing discipline, shedding peripheral bets, and leaning heavily into its proprietary B2B SaaS moat, the company has derisked its fundamental business model. While top-line revenue has temporarily stabilized as a result of this restructuring, the staggering 46% contribution margins and successful UAE market penetration indicate that the engine is primed for efficient, scalable growth. As the company prepares for its anticipated public market debut, it stands not just as a pioneer of Indian healthtech, but as the foundational digital infrastructure upon which the sector will operate for the next decade.